Short-Term Effectiveness, Safety, and Potential Predictors of Response of Secukinumab in Patients with Severe Hidradenitis Suppurativa Refractory to Biologic Therapy: A Multicenter Observational Retrospective Study.
Pablo Fernandez-CrehuetSofía HaselgruberAlicia Padial-GomezFiorella Vasquez-ChinchayMaria Dolores Fernandez-BallesterosIrene López-RiquelmeDavid Jimenez-GalloJuan Manuel Segura-PalaciosMarisol Contreras-SteylsGiovana Fernanda Osorio-GómezJuan Carlos Hernández-RodríguezManuel Sanchez-DiazCarlos Cuenca-BarralesSalvador Arias-SantiagoMolina-Leyva AlejandroPublished in: Dermatology and therapy (2023)
Favorable short-term effectiveness and safety of secukinumab in the treatment of severe HS patients were observed. Female sex, lower BMI and a lower therapeutic burden may be associated with a higher probability of achieving HiSCR.
Keyphrases
- hidradenitis suppurativa
- ankylosing spondylitis
- end stage renal disease
- newly diagnosed
- ejection fraction
- early onset
- randomized controlled trial
- rheumatoid arthritis
- systematic review
- cross sectional
- body mass index
- mesenchymal stem cells
- risk factors
- systemic lupus erythematosus
- drug induced
- weight gain
- replacement therapy
- smoking cessation
- combination therapy